Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's EBIT?
- Corcept Therapeutics (CORT) reported EBIT of $41.3M in Q2 2026.
- How has Corcept Therapeutics's EBIT changed year-over-year?
- Corcept Therapeutics's EBIT increased by 54.8% year-over-year, from $26.68M to $41.3M.
- What is the long-term trend for Corcept Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Corcept Therapeutics's EBIT has grown at a -22.5% compound annual growth rate (CAGR), from $124.48M to $44.8M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Corcept Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude